青海春天(600381) - 2025 Q2 - 季度业绩预告

Qinghai Spring Pharmaceutical Resources Technology Co., Ltd. 2025 Semi-Annual Performance Forecast Current Period Performance Forecast The company expects to turn profitable in H1 2025 with net profit attributable to shareholders between RMB 0.96 million and RMB 1.38 million, despite a revenue decline and continued non-recurring loss 2025 H1 Performance Forecast | Metric | Estimated Amount (RMB) | Year-on-Year Change | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company | RMB 0.96 million to RMB 1.38 million | Turnaround to Profit | | Net Profit Attributable to Shareholders Excluding Non-recurring Items | RMB -1.36 million to RMB -1.80 million | - | | Operating Revenue | RMB 121.00 million to RMB 126.00 million | Decrease of 8.95% to 12.56% | - The performance forecast data is unaudited by a certified public accountant[5] Prior Period Performance Overview In H1 2024, the company reported a loss with net profit attributable to shareholders at RMB -59.87 million, operating revenue at RMB 138.38 million, and basic EPS at RMB -0.102 2024 H1 Prior Period Performance | Metric | 2024 Prior Period Amount (RMB) | | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company | RMB -59.87 million | | Net Profit Attributable to Shareholders Excluding Non-recurring Items | RMB -60.13 million | | Operating Revenue | RMB 138.38 million | | Basic Earnings Per Share | RMB -0.102/share | Key Reasons for Current Period Performance Change The company's turnaround to profitability is primarily driven by improved gross margin from product mix optimization and effective control over selling and administrative expenses, despite a revenue decline - The year-on-year decrease in operating revenue is mainly due to changes in market conditions and the off-season for the main business in the second quarter[8] - Net profit attributable to shareholders achieved profitability, primarily benefiting from increased average gross margin and gross profit due to changes in sales product structure, alongside reduced selling and administrative expenses[8] Risk Warning The company warns investors that this performance forecast is a preliminary, unaudited estimate, and final accurate financial data will be based on the officially disclosed 2025 semi-annual report - This performance forecast data is a preliminary estimate, and the specific accurate financial data will be subject to the company's officially disclosed 2025 semi-annual report, reminding investors to be aware of investment risks[9]